m6A RNA methylation in age-related cognitive decline and AD: Novel targets for developing potential therapies
Alba Irisarri Martinez, Aina Bellver Sanchis, David Valle Garcia, Mercè Pallàs Lliberia, Christian Griñán Ferré · FENS Forum 2024
Alzheimer’s Disease (AD) is a progressive brain disorder known to be the most common type of dementia in aging population, yet therapeutical curative approaches remain unmet. Epigenetics is one of the many factors that contribute to the development of the disease, and it is considered a potential therapeutical target on the search of novel pharmacological drugs. Particularly, N6-methyladenosine (m6A) RNA methylation has been shown to be one of the main dynamically reversible epigenetic modifications contributing to the progression of neural degeneration. This way, abnormal levels of m6A have
ePoster · Neuroscience